| Title: | A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer |
| Authors: | Yoshimura, Takaaki Browse this author →KAKEN DB |
| Nishioka, Kentaro Browse this author →KAKEN DB |
| Hashimoto, Takayuki Browse this author →KAKEN DB |
| Seki, Kazuya Browse this author |
| Kogame, Shouki Browse this author |
| Tanaka, Sodai Browse this author →KAKEN DB |
| Kanehira, Takahiro Browse this author |
| Tamura, Masaya Browse this author →KAKEN DB |
| Takao, Seishin Browse this author →KAKEN DB |
| Matsuura, Taeko Browse this author →KAKEN DB |
| Kobashi, Keiji Browse this author |
| Kato, Fumi Browse this author →KAKEN DB |
| Aoyama, Hidefumi Browse this author →KAKEN DB |
| Shimizu, Shinichi Browse this author →KAKEN DB |
| Keywords: | Urethra-sparing radiotherapy |
| Prostate cancer |
| Intensity-modulated proton therapy |
| Tumor control probability |
| Normal tissue complication probability |
| Issue Date: | Oct-2021 |
| Publisher: | Elsevier |
| Journal Title: | Physics and Imaging in Radiation Oncology |
| Volume: | 20 |
| Start Page: | 23 |
| End Page: | 29 |
| Publisher DOI: | 10.1016/j.phro.2021.09.006 |
| Abstract: | Background and Purpose: Urethra-sparing radiation therapy for localized prostate cancer can reduce the risk of radiation-induced genitourinary toxicity by intentionally underdosing the periurethral transitional zone. We aimed to compare the clinical impact of a urethra-sparing intensity-modulated proton therapy (US-IMPT) plan with that of conventional clinical plans without urethral dose reduction. Materials and Methods: This study included 13 patients who had undergone proton beam therapy. The prescribed dose was 63 GyE in 21 fractions for 99% of the clinical target volume. To compare the clinical impact of the US-IMPT plan with that of the conventional clinical plan, tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated with a generalized equivalent uniform dose-based Lyman-Kutcher model using dose volume histograms. The endpoints of these model parameters for the rectum, bladder, and urethra were fistula, contraction, and urethral stricture, respectively. Results: The mean NTCP value for the urethra in US-IMPT was significantly lower than that in the conventional clinical plan (0.6% vs. 1.2%, p < 0.05). There were no statistically significant differences between the conventional and US-IMPT plans regarding the mean minimum dose for the urethra with a 3-mm margin, TCP value, and NTCP value for the rectum and bladder. Additionally, the target dose coverage of all plans in the robustness analysis was within the clinically acceptable range. Conclusions: Compared with the conventional clinically applied plans, US-IMPT plans have potential clinical advantages and may reduce the risk of genitourinary toxicities, while maintaining the same TCP and NTCP in the rectum and bladder. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/83937 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
